Clinical pharmacogenetics in psychiatry

Psychopharm Review

Volumn 44, Issue 7, 2009, Pages 49-55

  Dantz, Bezalel ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ARIPIPRAZOLE; CITALOPRAM; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DESIPRAMINE; DIAZEPAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; HLA B ANTIGEN; IMIPRAMINE; MOCLOBEMIDE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; TRAZODONE; TRIAZOLAM; UNINDEXED DRUG; VENLAFAXINE; ZALEPLON; ZIPRASIDONE;

AFRICAN AMERICAN; ASIAN; BREAST CANCER; CANCER RECURRENCE; CAUCASIAN; CHINESE; CHROMOSOME 10; CROSS REACTION; DNA POLYMORPHISM; DRUG CLEARANCE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG TOLERABILITY; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HISPANIC; HUMAN; MAJOR DEPRESSION; PHARMACOGENETICS; PHENOTYPE; PHENOTYPIC VARIATION; REVIEW; STEVENS JOHNSON SYNDROME; SWEDEN; TOXIC EPIDERMAL NECROLYSIS; UNSPECIFIED SIDE EFFECT;

EID: 78649259337     PISSN: 19369255     EISSN: None     Source Type: Trade Journal    
DOI: 10.1097/01.IDT.0000352539.85714.56     Document Type: Review

References (61)

1. Stahl SM. Personalized medicine, pharmacogenomics, and the practice of psychiatry: on the threshold of predictive therapeutics in psychopharmacology? CNS Spectr 2008;13(2):115-118.
2. McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006;78(5):804-814.
3. Arranz MJ, Kapur S. Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull 2008;34(6):1130-1144.
4. de Leon J. Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacology 2009;34(1):159-172.
5. Stearns V, Rae JM. Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response? Expert Rev Mol Med 2008;10:e34.
6. InternationalWarfarin Pharmacogenetics Consortium, Klein TE, Altman RB, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360(8):753-764.
7. U.S. Food and Drug Administration. Table of valid genomic biomarkers in the context of approved drug labels. Available at: www.fda.gov/cder/genomics/ genomic-biomarkers-table.htm.
8. DahlML, ScordoMG. Cytochromes P450. In: Gorwood P, HamonMD, eds. Psychopharmacogenetics. NewYork: Springer;2006:443-478.
9. Indiana University School of Medicine, Division of Clinical Pharmacology website. P450 drug interaction table.Available at: www.medicine.iupui. edu/clinpharm/ddis/table.asp.
10. de Leon J, Arranz MJ, Ruano G. Pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clin Lab Med 2008;28(4):599-617.
11. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002;3(2):229-243.
12. de Leon J,Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006;47(1):75-85.
13. Higgins MJ, Rae JM, Flockhart DA, et al. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing? J Natl Compr Canc Netw 2009;7(2):203-213.
14. Jin Y, Desta Z, Stearns V, et al. CYP2D6 Genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30-39.
15. Bertilsson L. Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects. Clin Pharmacol Ther 2007;82(5):606-609.
16. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmcogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004;9(5):442-473.
17. Rau T,Wohlleben G,Wuttke H, et al. CYP2D6 gnotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther 2004;75(5):386-393.
18. McAlpine DE, O'Kane DJ, Black JL, et al. Cytochrome P450 2D6 genotype variation and venlafaxine dosage. Mayo Clinic Proceedings 2007; 82(9):1065-1068.
19. SteimerW, Zopf K, von Amelunxen S, et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 2005;51(2):376-385.
20. Murphy GM Jr, Kremer C, Rodrigues HE, et al. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003;160(10):1830-1835.
21. Bijl MJ, Visser LE, HofmanA, et al. Influence of the CYP2D6.*4 polymorphism on dose, switching and discontinuation of antidepressants. Br J Clin Pharmacol 2008;65(4):558-564.
22. Thakur M, Grossman I, McCrory DC, et al. Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors. Genet Med 2007;9(12):826-835.
23. Schillevoort I, de Boer A, van derWeide J, et al. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a casecontrol study. Pharmacogenetics 2002;12(3):235-240.
24. Mulder H,Wilmink FW, Belitser SV, et al. The association between Cytochrome P450-2D6 genotype and prescription of antiparkinsonian drugs in hospitalized psychiatric patients using antipsychotics: a retrospective follow-up study. J Clin Psychoparmacol 2006;26(2):212-215.
25. Brockmoller J, Kirchheiner J, Schmider J, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002;72(4):438-452.
26. Crescenti A, Mas S, Gasso P, et al. CYP2D6.*3, .*4, .*5 and .*6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy. Clin Exp Pharmacol Physiol 2008;35(7):807-811.
27. Patsopoulos NA, Ntzani EE, Zintzaras E, et al. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet Genomics 2005;15(3):151-158.
28. Grossman I, Sullivan PF,Walley N, et al. Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genet Med 2008;10(10):720-729.
29. Wedlund PJ. The CYP2C19 enzyme polymorphism. Pharmacology 2000;61(3):174-183.
30. Bertilsson L, Henthorn TK, Sanz E, et al. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 1989;45(4):348-355.
31. Inomata S, Nagashima A, Itagaki F, et al. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin Pharmacol Ther 2005;78(6):647-655.
32. Kropp S, Lichtinghagen R,Winterstein K, et al. Cytochrome P-450 2D6 and 2C19 polymorphisms and length of hospitalization in psychiatry. Clin Lab 2006;52:237-240.
33. Peters EG, Slager SL, Kraft JB, et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR.*D sample. PLoS ONE 2008;3(4):e1872.
34. Tiwari AK, Deshpande SN, Lerer B, et al. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism. Pharmacogenomics J 2007;7(5):305-311.
35. Sachse C, BrockmVoller J, Bauer S, et al. Functional significance of a C- >A polymorphism in intron 1 of the cytochrome p450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47(4):445-449.
36. Aklillu E, Carrillo JA, Makonnen E, et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 2003;64(3):659-669.
37. Hamdy SI, Hiratsuka M, Narahara K, et al. Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population. Br J Clin Pharmacol 2003;55(3):321-324.
38. Kootstra-Ros JE, SmallegoorW, van derWeide J. The cytochrome P450 CYP1A2 genetic polymorphisms .*1F and .*1D do not affect clozapine clearance in a group of schizophrenic patients. Ann Clin Biochem 2005;42(Pt 3):216-219.
39. Eap CB, Bender S, Sirot EJ, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol 2004;24:214-219.
40. Nozawa M, Ohnuma T, Matsubara Y, et al. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Ther Drug Monit 2008;30(1):35-40.
41. van derWeide J, Steijns LS, vanWeelden MJ. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 2003;13(3):169-172.
42. Tiwari AK, Deshpande SN, Rao AR, et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schizophr Res 2005;75(1):21-26.
43. Matsumoto C, Ohmori O, Shinkai T, et al. Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia. Psychiatr Genet 2004;14(4):209-213.
44. Gunes A, Dahl ML. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics 2008;9(5):625-637.
45. Genelex website. DNA drug reaction testing. Available at: www. healthanddna.com/drug-safety-dna-testing/dna-drug-reaction-testing.html.
46. ChungWH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007;7(4):317-323.
47. ChungWH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428(6982):486.
48. Hung SI, ChungWH, Jee SH, et al. Genetic susceptibility to carbamazepine- induced cutaneous adverse drug reactions. Pharmacogenet Genomics. 2006;16(4):297-306.
49. Chang CC, Too CL, Murad S, et al. Association of HLA-B.*1502 with carbamazepine- induced toxic epidermal necrolysis and Stevens-Johnson syndrome in Malaysian population. Proceedings of the 7th Asian-Oceanian Epilepsy Congress, Xiamen, 2008.
50. RomphrukA, Phongaen K, Chotechai J, et al. HLA-B.*15 subtypes in the population of north-eastern Thailand. Eur J Immunogenet 2003;30(2):153-158.
51. Man CB, Kwan P, Baum L, et al. Association between HLA-B.*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007;48(5):1015-1018.
52. Alfirevic A, Jorgensen AL,Williamson PR, et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006;7(6):813-818.
53. Kashiwagi M, Aihara M, Takahashi Y, et al. J Human leukocyte antigen genotypes in carbamazepine-induced severe cutaneous adverse drug response in Japanese patients. J Dermatol 2008;35(10):683-685.
54. Lim KS, Kwan P, Tan CTAssociation of HLA-B.*1502 allele and carbamazepine- induced severe adverse cutaneous drug reaction among Asians, a review. Neurology Asia 2008;13:15-21.
55. U.S. Food and DrugAdministration. Information for healthcare professionals: carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics). Available at: www.fda.gov/cder/drug/InfoSheets/HCP/carbamazepineHCP. html.
56. Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLAB.* 1502 allele in Thai population. Epilepsia 2008;49(12):2087-2091.
57. Chen YC, Chu CY, Hsiao CH. Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B.*1502 genotype. J Eur Acad Dermatol Venereol 2008 Sep 9 (Epub ahead of print).
58. Arroyo S, de la Morena A. Life-threatening adverse events of antiepileptic drugs. Epilepsy Res 2001;47(1-2):155-174.
59. Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008;18(2):99-107.
60. Mayo Medical Laboratories. Unit Code 89347: HLAB 1502 genotype, carbamazepine hypersensitivity.Available at: www.mayomedicallaboratories. com/test-catalog/Fees+and+Coding/89347.
61. Mayo Medical Laboratories. Unit Code 83180: Cytochrome P450 2D6. Available at: www.mayomedicallaboratories.com/testcatalog/Fees+and+ Coding/83180.